Agios plans Q2 sNDA filing for mitapivat in sickle cell disease while citing >$10B 2030 market opportunity
Agios Pharmaceuticals, Inc. · PHARMACEUTICAL PREPARATIONS · Now $29.40
-1.7% in 3d after detection
Post-detection moves
1h
—
1d
-0.2%
3d
-1.7%
7d
-0.9%
30d
—
Get alerts like this in real time
Push notifications the moment a signal fires. No spam, no crypto, no fluff.
Download for iOS